Method of treating a methionine-dependent cancer
The present specification relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.
1. A method of treating cancer or reducing the risk of recurrence of cancer in a subject who has previously had an anti-cancer therapy, the method comprising the step of administering an inhibitor of methionine adenosyltransferase 2A (MAT2A) to the subject to inhibit proliferation of a tumor initiating cell or eliminate a tumor initiating cell in the cancer, wherein the tumor initiating cell expresses MAT2A, cluster of differentiation 166 (CD166), serine hydroxymethyltransferase 2 (SHMT2) and methylthioadenosine phosphorylase (MTAP), thereby treating or reducing the risk of recurrence of cancer in the subject.
2. The method of claim 1 , wherein the cancer is a metastatic or recurrent cancer.
3. The method of claim 1 , wherein the cancer a methionine-dependent cancer.
4. The method of claim 1 , wherein the cancer is a MAT2A-dependent cancer.
5. The method of claim 1 , wherein the inhibitor of MAT2A is selected from the group consisting of FIDAS-5, FIDAS-3, PF-9366 and AG-270.
6. The method of claim 1 , wherein the cancer is a lung cancer.